Company Profile

NKT Therapeutics Inc
Profile last edited on: 6/15/2021      CAGE: 5BWU0      UEI: W5MBG2MZJBK1

Business Identifier: Therapeutics based on unique immune cells called natural killer T (NKT) cells
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

800 Winter Street Suite 350
Waltham, MA 02451
   (781) 684-0290
Location: Single
Congr. District: 05
County: Middlesex

Public Profile

NKT Therapeutics is a biotechnology company organized around development of an immune cell-targeting process: therapeutics targeting NKT cells to treat sickle cell diseases, autoimmune and inflammatory disease, cancer, and asthma. NKT cells--natural killer T cells--are a rare but central component of the immune system that play a pivitol role in human health and disease. By targeting these cells, NKT Therapeutics can develop selective immune modulators with disease-treating potential. As of 2014 NKT's NKTT320 candidate for the treatment of sickle cell diseases had completed dosing in its phase 1b trial. Other candidates were in pre-clinical development for cancer and autoimmune disorders.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2014 1 NIH $149,952
Project Title: Depletion of iNKT Cells in the Treatment of Hypoxic Crises in Sickle Cell Mice

Key People / Management

  Robert Mashal -- Chief Executive Officer And President

  Ron Goldstein -- Vice President, Finance

  Robert Schaub -- Chief Scientific Officer

  Mark Tepper -- Founder

  Alem Truneh -- Founder Former CSO and EVP R&D